Premium
S2‐01–05: The use of genetic variants as biomarkers in Alzheimer's disease
Author(s) -
Mayeux Richard
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.273
Subject(s) - apolipoprotein e , disease , biomarker , alzheimer's disease , genetic predisposition , psen1 , allele , medicine , prnp , genetic association , biology , genetics , bioinformatics , oncology , immunology , genotype , presenilin , gene , single nucleotide polymorphism
dependent response utilizing only five individuals per group. Conclusions: We have demonstrated that Abeta synthesis and clearance can be directly measured in the CNS of humans and that one can detect a significant change in the CNS generation of Abeta following peripheral administration of a secretase inhibitor. This technique is being utilized to study the pathophysiology of Abeta in AD patients compared to controls.